{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:33Z","timestamp":1787026593158,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Interleukin (IL)-1 inhibitors are largely employed in patients with Still\u2019s disease; in cases with refractory arthritis, IL-6 inhibitors have shown to be effective on articular inflammatory involvement. The aim of the present study is to assess any difference in the effectiveness of the IL-1\u03b2 antagonist canakinumab prescribed as first-line biologic agent between the systemic and the chronic-articular Still\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were drawn from the retrospective phase of the AutoInflammatory Disease Alliance (AIDA) international registry dedicated to Still\u2019s disease. Patients with Still\u2019s disease classified according to internationally accepted criteria (Yamaguchi criteria and\/or Fautrel criteria) and treated with canakinumab as first-line biologic agent were enrolled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 26 patients (17 females, 9 males; 18 patients developing Still\u2019s disease after the age of 16 years) were enrolled; 16 (61.5%) patients suffered from the systemic pattern of the disease; 10 (38.5%) patients suffered from the chronic-articular type. No differences were observed between the systemic and the chronic-articular Still\u2019s disease in the frequency of complete response, of flares after the start of canakinumab (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.701) and in the persistence in therapy (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.62). No statistical differences were observed between the two groups after 3 months, 12 months and at the last assessment in the decrease of: the systemic activity score (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.06,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.17,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.17, respectively); the disease activity score on 28 joints (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.54,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.77,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.98, respectively); the glucocorticoid dosage (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.15,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.50, and\n                      <jats:italic>p<\/jats:italic>\n                      = 0.50, respectively); the use of concomitant disease modifying anti-rheumatic drugs (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.10,\n                      <jats:italic>p<\/jats:italic>\n                      = 1.00, and\n                      <jats:italic>p<\/jats:italic>\n                      = 1.00, respectively). No statistically significant differences were observed in the decrease of erythrocyte sedimentation rate (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.34), C reactive protein (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.48), and serum ferritin levels (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.34) after the start of canakinumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Canakinumab used for Still\u2019s disease has been effective in controlling both clinical and laboratory manifestations disregarding the type of disease course when used as first-line biotechnological agent. These excellent results might have been further enhanced by the early start of IL-1 inhibition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2022.1071732","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T02:02:17Z","timestamp":1671674537000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Canakinumab as first-line biological therapy in Still\u2019s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry"],"prefix":"10.3389","volume":"9","author":[{"given":"Antonio","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Caggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Gaggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Campochiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Balistreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Laskari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"Tufan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaafar","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim A.","family":"Almaghlouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Wi\u0119sik-Szewczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset still\u2019s disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies.","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum."},{"key":"B2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","article-title":"Pathogenesis of adult-onset still\u2019s disease: new insights from the juvenile counterpart.","volume":"61","author":"Jamilloux","year":"2015","journal-title":"Immunol Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12969-015-0047-3","article-title":"Gene-expression analysis of adult-onset still\u2019s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity.","volume":"13","author":"Nirmala","year":"2015","journal-title":"Pediatr Rheumatol Online J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/art.1780300209","article-title":"Adult-onset still\u2019s disease. Clinical course and outcome.","volume":"30","author":"Cush","year":"1987","journal-title":"Arthritis Rheum."},{"key":"B5","first-page":"424","article-title":"Preliminary criteria for classification of adult still\u2019s disease.","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/00005792-200205000-00003","article-title":"Proposal for a new set of classification criteria for adult-onset still disease.","volume":"81","author":"Fautrel","year":"2002","journal-title":"Medicine."},{"key":"B7","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, edmonton, 2001.","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus.","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3944586","article-title":"Derivation and validation of adult still activity score (SAS).","author":"Kalyoncu","year":"2022","journal-title":"Joint Bone Spine."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.3899\/jrheum.100247","article-title":"Clinical manifestations but not cytokine profiles differentiate adult-onset still\u2019s disease and sepsis.","volume":"37","author":"Rau","year":"2010","journal-title":"J Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12916-016-0738-8","article-title":"Adult-onset still\u2019s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers.","volume":"14","author":"Ruscitti","year":"2016","journal-title":"BMC Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/acr.24042","article-title":"2019 update of the american college of rheumatology recommended rheumatoid arthritis disease activity measures.","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3899\/jrheum.130835","article-title":"Description of active joint count trajectories in juvenile idiopathic arthritis.","volume":"41","author":"Berard","year":"2014","journal-title":"J Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","article-title":"Efficacy of anakinra in refractory adult-onset still\u2019s disease: multicenter study of 41 patients and literature review.","volume":"94","author":"Ortiz-Sanju\u00e1n","year":"2015","journal-title":"Medicine."},{"key":"B15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13075-019-1838-6","article-title":"Adult-onset still\u2019s disease biological treatment strategy may depend on the phenotypic dichotomy.","volume":"21","author":"Vercruysse","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"109143","DOI":"10.1016\/j.clim.2022.109143","article-title":"Update of evidence- and consensus-based guidelines for the treatment of juvenile idiopathic arthritis (JIA) by the german society of pediatric and juvenile rheumatic diseases (GKJR): new perspectives on interdisciplinary care.","volume":"245","author":"Oommen","year":"2022","journal-title":"Clin Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"152089","DOI":"10.1016\/j.semarthrit.2022.152089","article-title":"Efficacy and safety of tocilizumab in adult-onset still\u2019s disease: real-life experience from the international AIDA registry.","volume":"57","author":"Sota","year":"2022","journal-title":"Semin Arthritis Rheum."},{"key":"B18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fphar.2019.00296","article-title":"Long-term retention rate of anakinra in adult onset still\u2019s disease and predictive factors for treatment response.","volume":"10","author":"Vitale","year":"2019","journal-title":"Front Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/rheumatology\/keab619","article-title":"Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort.","volume":"61","author":"De Matteis","year":"2022","journal-title":"Rheumatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/14397595.2020.1783163","article-title":"Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients.","volume":"31","author":"Nishimura","year":"2021","journal-title":"Mod Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"8054961","DOI":"10.1155\/2020\/8054961","article-title":"Real-life data on the efficacy of canakinumab in patients with adult-onset still\u2019s disease.","volume":"2020","author":"Vitale","year":"2020","journal-title":"Mediators Inflamm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fmed.2020.00042","article-title":"Comparison of early vs. delayed anakinra treatment in patients with adult onset still\u2019s disease and effect on clinical and laboratory outcomes.","volume":"7","author":"Vitale","year":"2020","journal-title":"Front Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"878797","DOI":"10.3389\/fmed.2022.878797","article-title":"Development and implementation of the AIDA international registry for patients with still\u2019s disease.","volume":"9","author":"Vitale","year":"2022","journal-title":"Front Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","article-title":"Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.","volume":"77","author":"Ruperto","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/rheumatology\/40.12.1398","article-title":"Cytokine and immunogenetic profiles in Japanese patients with adult still\u2019s disease. Association with chronic articular disease.","volume":"40","author":"Fujii","year":"2001","journal-title":"Rheumatology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","article-title":"Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles.","volume":"61","author":"Shimizu","year":"2013","journal-title":"Cytokine."},{"key":"B28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12969-021-00510-8","article-title":"Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry.","volume":"19","author":"Lainka","year":"2021","journal-title":"Pediatr Rheumatol Online J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1546-0096-12-28","article-title":"Development of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course.","volume":"12","author":"H\u00fcgle","year":"2014","journal-title":"Pediatr Rheumatol Online J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for treatment of adult-onset still\u2019s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B33","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3899\/jrheum.180331","article-title":"Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis.","volume":"46","author":"Saccomanno","year":"2019","journal-title":"J Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","article-title":"Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.","volume":"19","author":"Horneff","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13075-019-1843-9","article-title":"Efficacy of canakinumab as first-line biologic agent in adult-onset still\u2019s disease.","volume":"21","author":"Cavalli","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphar.2016.00380","article-title":"A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study.","volume":"7","author":"Vitale","year":"2016","journal-title":"Front Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40744-021-00422-9","article-title":"Similar clinical outcomes in patients with systemic juvenile idiopathic arthritis and adult-onset still\u2019s disease treated with canakinumab: bayesian and population model-based analyses.","volume":"9","author":"Dunger-Baldauf","year":"2022","journal-title":"Rheumatol Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.semarthrit.2020.10.011","article-title":"Outcome of refractory to conventional and\/or biologic treatment adult still\u2019s disease following canakinumab treatment: countrywide data in 50 patients.","volume":"51","author":"Laskari","year":"2021","journal-title":"Semin Arthritis Rheum."},{"key":"B39","first-page":"668","article-title":"Efficacy and safety of canakinumab in patients with still\u2019s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.","volume":"36","author":"Feist","year":"2018","journal-title":"Clin Exp Rheumatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1071732\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T02:02:20Z","timestamp":1671674540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1071732\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":39,"alternative-id":["10.3389\/fmed.2022.1071732"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1071732","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"article-number":"1071732"}}